Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 in HER2- HR+ Metastatic Breast Cancer with Bone Metastases
NCT02258464Phase 2Terminated
- Sponsor
- Bayer
- Start
- Mar 2015
- Primary completion
- Aug 2019
- Modality
- Radiopharmaceutical
- Countries
- 20
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Radium-223 with Placebo (2 arms). Primary endpoint: Symptomatic Skeletal Event Free Survival. Started Mar 2015; status: terminated.
02
Drugs
radium-223 dichloride
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02258464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02258464.